Cellebrite DI Ltd. $CLBT Shares Bought by Nine Ten Capital Management LLC

Key Points

• Nine Ten Capital Management increased its Cellebrite DI stake by 19.8% in the second quarter, acquiring 682,933 additional shares and bringing its holdings to 4.13 million shares valued at approximately $60.3 million.
• CLBT shares opened at $11.45, below their 50- and 200-day moving averages, while institutional investors collectively own 45.88% of the stock. Insiders sold about $5.0 million of shares over the past 90 days.
• Analysts remain generally positive, with five Buy ratings and one Sell rating, producing a consensus “Moderate Buy” rating and an average price target of $16.70 despite multiple target-price reductions.

Nine Ten Capital Management LLC lifted its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 19.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,126,808 shares of the company's stock after acquiring an additional 682,933 shares during the quarter. Cellebrite DI comprises about 18.7% of Nine Ten Capital Management LLC's investment portfolio, making the stock its 3rd biggest holding. Nine Ten Capital Management LLC owned 1.65% of Cellebrite DI worth $60,251,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in CLBT. Towarzystwo Funduszy Inwestycyjnych PZU SA increased its position in shares of Cellebrite DI by 81.0% during the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company's stock valued at $34,000 after purchasing an additional 850 shares during the period. Advisory Services Network LLC bought a new position in Cellebrite DI during the third quarter valued at about $40,000. CWM LLC grew its holdings in Cellebrite DI by 57.0% during the fourth quarter. CWM LLC now owns 2,449 shares of the company's stock worth $44,000 after acquiring an additional 889 shares during the period. Elevation Wealth Partners LLC bought a new stake in Cellebrite DI in the second quarter worth about $44,000. Finally, Vestcor Inc acquired a new stake in Cellebrite DI in the 3rd quarter valued at about $70,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Cellebrite DI Price Performance

Shares of CLBT stock opened at $11.45 on Wednesday. Cellebrite DI Ltd. has a fifty-two week low of $9.58 and a fifty-two week high of $19.98. The stock's 50-day moving average is $13.94 and its two-hundred day moving average is $13.64. The firm has a market cap of $2.86 billion, a P/E ratio of 52.05, a PEG ratio of 1.76 and a beta of 1.15.

Insider Buying and Selling

In related news, insider Thomas Hogan sold 25,299 shares of the business's stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $11.29, for a total value of $285,625.71. Following the completion of the sale, the insider directly owned 765,249 shares in the company, valued at approximately $8,639,661.21. The trade was a 3.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CRO Marcus Jewell sold 12,562 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $11.24, for a total value of $141,196.88. Following the transaction, the executive owned 427,128 shares in the company, valued at approximately $4,800,918.72. This trade represents a 2.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 329,658 shares of company stock worth $4,970,967 over the last ninety days. 5.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on CLBT shares. JPMorgan Chase & Co. reduced their target price on shares of Cellebrite DI from $20.00 to $16.00 and set an "overweight" rating for the company in a report on Friday, August 14th. Needham & Company LLC cut their price objective on Cellebrite DI from $15.00 to $12.50 and set a "buy" rating for the company in a research report on Friday, August 14th. Lake Street Capital reduced their price objective on Cellebrite DI from $21.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, August 14th. Weiss Ratings lowered Cellebrite DI from a "sell (d+)" rating to a "sell (d)" rating in a research report on Thursday, August 27th. Finally, DA Davidson reduced their target price on Cellebrite DI from $22.00 to $15.00 and set a "buy" rating for the company in a report on Friday, August 14th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Cellebrite DI currently has a consensus rating of "Moderate Buy" and an average target price of $16.70.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.

Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.